Total Visits

Views
Preliminary safety results of regorafenib (REG) as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients (pts) with metastatic colorectal cancer (mCRC): A phase II study of the Spanish Cooperative Group for Digestive66

Select a period of time:

Views

Views
October 20251
November 20251
December 20250
January 20260
February 20260
March 20260
April 20260
Download CSV file
 untranslated
 untranslated

Top country views

Views
Argentina1
Brazil1
 

Top cities views

Views
Corrientes1
São Paulo1